Focus: Currax Pharmaceuticals is a specialty pharmaceutical company headquartered in Brentwood, Tennessee, focused on small molecules and specialty generics in neurology. The company derives 45% of revenue from TREXIMET, indicating significant product concentration.
Profile data last refreshed 22h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Currax Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Currax Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Currax Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product losing exclusivity in April 2026; represents 45% of company revenue and faces imminent generic erosion.
Secondary revenue driver in sleep disorder market with patent protection until September 2030; part of patent cliff exposure at $907K.
Nasal powder formulation offering longest patent runway until October 2034 with moderate Part D spending in migraine market.
1 discontinued, 0 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo